MXPA02011587A - Reactivos para la seleccion de celulas y metodos de uso. - Google Patents

Reactivos para la seleccion de celulas y metodos de uso.

Info

Publication number
MXPA02011587A
MXPA02011587A MXPA02011587A MXPA02011587A MXPA02011587A MX PA02011587 A MXPA02011587 A MX PA02011587A MX PA02011587 A MXPA02011587 A MX PA02011587A MX PA02011587 A MXPA02011587 A MX PA02011587A MX PA02011587 A MXPA02011587 A MX PA02011587A
Authority
MX
Mexico
Prior art keywords
peptide
cell
ligand
provides
conjugate
Prior art date
Application number
MXPA02011587A
Other languages
English (en)
Inventor
Epps Dennis E Van
Original Assignee
Nexell Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexell Therapeutics Inc filed Critical Nexell Therapeutics Inc
Publication of MXPA02011587A publication Critical patent/MXPA02011587A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

La presente invencion proporciona conjugados peptido-ligando que contienen un peptido, donde una forma libre del peptido puede desplazar a un segundo ligando especifico para el peptido. La invencion tambien proporciona un metodo para seleccionar una celula. El metodo incluye los pasos de: poner en contacto una poblacion de celulas con un conjugado peptido-ligando, en donde el conjugado contiene un primer ligando especifico para una celula en la poblacion conjugado a un peptido que puede desplazar a un segundo ligando especifico para el peptido, formando de este modo un complejo celula-conjugado; poner en contacto el conjugado peptido-ligando con el segundo ligando; y separar el complejo celula-conjugado. El metodo ademas puede incluir el paso de adicionar una forma libre del peptido para liberar la celula del complejo. La invencion tambien proporciona una subpoblacion de celulas que contiene 2 o mas celulas aisladas especificas y los metodos para aislar las subpoblaciones de celulas. La invencion ademas proporciona un metodo para diagnosticar un estado utilizando los conjugados peptido-ligando. La invencion ademas proporciona un kit para aislar una celula, el cual contiene un peptido que puede desplazar a un anticuerpo especifico para el peptido y el anticuerpo.
MXPA02011587A 2000-05-23 2001-05-23 Reactivos para la seleccion de celulas y metodos de uso. MXPA02011587A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57878400A 2000-05-23 2000-05-23
US65946900A 2000-09-11 2000-09-11
PCT/US2001/016840 WO2001090153A2 (en) 2000-05-23 2001-05-23 Reagents for cell selection and methods of use

Publications (1)

Publication Number Publication Date
MXPA02011587A true MXPA02011587A (es) 2004-07-30

Family

ID=27077582

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02011587A MXPA02011587A (es) 2000-05-23 2001-05-23 Reactivos para la seleccion de celulas y metodos de uso.

Country Status (8)

Country Link
US (1) US20030119070A1 (es)
EP (1) EP1317476B1 (es)
JP (1) JP2004501110A (es)
AT (1) ATE382633T1 (es)
AU (2) AU2001274931B2 (es)
DE (1) DE60132221T2 (es)
MX (1) MXPA02011587A (es)
WO (1) WO2001090153A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030219445A1 (en) * 2000-05-23 2003-11-27 Nexell Therapeutics, Inc. Reagents for cell selection and methods of use
DE10256042B4 (de) * 2002-11-30 2006-06-08 Universität Potsdam Verfahren zur Selektion von Zellen, die spezifisch bindende Moleküle produzieren
DE10310082A1 (de) * 2003-03-07 2004-09-16 Ktb Tumorforschungsgesellschaft Mbh Protein-bindende Doxorubicin-Peptid-Derivate
US9140707B2 (en) * 2007-08-10 2015-09-22 University Of Louisville Research Foundation, Inc. Sensors and methods for detecting diseases caused by a single point mutation
WO2009079922A1 (fr) * 2007-12-13 2009-07-02 Shanghai Guojian Bio-Tech Institute Anticorps monoclonal anti-cd34 humanisé, sa préparation et ses utilisations
US20100279322A1 (en) * 2009-05-04 2010-11-04 Creatv Microtech, Inc. Direct detection of intracellular fluorescently tagged cells in solution
CN105277703A (zh) * 2014-07-23 2016-01-27 江苏维赛科技生物发展有限公司 一种快速检测农作物中代森环含量的试剂盒
KR101697473B1 (ko) * 2014-11-26 2017-01-18 주식회사 녹십자랩셀 T 세포를 이용한 자연살해세포의 배양방법
JP7272590B2 (ja) * 2017-07-11 2023-05-12 国立大学法人富山大学 細胞の選択的分離用又は細胞培養用ポリマーにより被覆された基体
AU2018316343A1 (en) 2017-08-11 2020-02-13 Genentech, Inc. Anti-CD8 antibodies and uses thereof
CN114173662A (zh) * 2019-07-12 2022-03-11 路易斯赖登创新公司 便携式ecg设备和包括该便携式ecg设备的ecg系统
EP4004545B1 (en) * 2020-01-31 2022-11-02 Cell.copedia GmbH Methods of isolating a biological entity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988621A (en) * 1985-05-24 1991-01-29 La Jolla Cancer Research Foundation Peptides in cell detachment and aggregation
US5262334A (en) * 1986-01-30 1993-11-16 Fred Hutchinson Cancer Research Center Method for immunoselection of cells using avidin and biotin
US5536475A (en) * 1988-10-11 1996-07-16 Baxter International Inc. Apparatus for magnetic cell separation
GB8916859D0 (en) * 1989-07-24 1989-09-06 Dynal As Hapten linking
US5646001A (en) * 1991-03-25 1997-07-08 Immunivest Corporation Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof
CA2141428A1 (en) * 1992-07-28 1994-02-03 Steven Kessler Methods for positive immunoselection of stem cells
JPH09502351A (ja) * 1993-09-08 1997-03-11 バクスター、インターナショナル、インコーポレイテッド 正の細胞選択及び遊離のためのビオチン類縁体接合抗体
US5968753A (en) * 1994-06-14 1999-10-19 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
IL114149A0 (en) * 1995-06-14 1995-10-31 Yeda Res & Dev Modified avidin and streptavidin molecules and use thereof
DE19641876B4 (de) * 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
US5985658A (en) * 1997-11-14 1999-11-16 Health Research Incorporated Calmodulin-based cell separation technique
DE69841894D1 (de) * 1997-11-21 2010-10-21 Merck Serono Biodevelopment Sa Äusseres Membranpolypeptid von Chlamydia pneumoniae sowie Fragmente davon und deren Verwendung, insbesondere zur Diagnose, Prävention und Behandlung einer Infektion
US6395890B1 (en) * 1998-02-20 2002-05-28 Zymogenetics, Inc. Nucleic acids encoding connective tissue growth factor homologs
AU4094099A (en) * 1998-05-22 1999-12-13 Osiris Therapeutics, Inc. Production of megakaryocytes by co-culturing human mesenchymal stem cells with cd34+ cells
WO1999061587A1 (en) * 1998-05-29 1999-12-02 Osiris Therapeutics, Inc. Human cd45+ and/or fibroblast + mesenchymal stem cells
AU3728400A (en) * 1999-03-12 2000-10-04 Ortho-Mcneil Pharmaceutical, Inc. Method of isolating cd8+ cells, and related hybridoma cells, antibodies and polypeptides
US6184011B1 (en) * 1999-03-22 2001-02-06 Cbd Technologies, Ltd Method of releasing solid matrix affinity adsorbed particulates
US20030219445A1 (en) * 2000-05-23 2003-11-27 Nexell Therapeutics, Inc. Reagents for cell selection and methods of use
US7097835B2 (en) * 2001-07-18 2006-08-29 The Regents Of The University Of California Immunoselective targeting agents and methods of use thereof

Also Published As

Publication number Publication date
DE60132221T2 (de) 2009-01-02
DE60132221D1 (de) 2008-02-14
JP2004501110A (ja) 2004-01-15
EP1317476A2 (en) 2003-06-11
AU2001274931B2 (en) 2006-03-30
AU7493101A (en) 2001-12-03
EP1317476B1 (en) 2008-01-02
ATE382633T1 (de) 2008-01-15
WO2001090153A3 (en) 2003-03-20
WO2001090153A2 (en) 2001-11-29
US20030119070A1 (en) 2003-06-26
WO2001090153A8 (en) 2002-03-28

Similar Documents

Publication Publication Date Title
AU7493101A (en) Reagents for cell selection and methods of use
GB0001450D0 (en) Cell isolation method
DE69917051D1 (de) "flow-zytometrischer" vollblut- dendritzelle- immunfunctiontest
WO2002077604A3 (en) Labeled cells for use as an internal functional control in rare cell detection assays
EP1575295A3 (en) Method for the determination of a container track information
AU6050701A (en) Nucleic acid isolation
EP0803577A3 (en) Method for detecting and/or determining ATP from microorganism cells in a sample
AU7441498A (en) Immunoassay apparatus for diagnosis
EP0992794A3 (en) Enzyme-antibody complex and a method for manufacturing the same
DK0564494T3 (da) Testmetode og reagenssæt dertil
AU3059499A (en) Solid-phase method for antigen and antibody determinations in bloodgroup serology, and test kit
AU2002246792A1 (en) Identification of individual cells during kinetic assays
CA2246896A1 (en) Immunoassay utilizing two incubations with labelled antigen
WO2001092877A3 (en) Method of identifying and/or isolating stem cells
ATE285581T1 (de) Assay-verfahren
MX9708697A (es) Metodo para diagnostico cancer de prostata.
WO2001075449A1 (fr) Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif
DE69730327D1 (de) Marker für unfruchtbarkeit und/oder -fruchtbarkeit bei männern
WO2002051988A3 (en) Thymic epithelial progenitor cells and uses thereof
CA2230423A1 (en) In-situ cell extraction and assay method
WO2003098212A3 (en) Method of isolating an endotehelial cell and method of donor specific crossmatching
AU2001270505A1 (en) Method and apparatus for early diagnosis of bladder tumor in urine samples
SE9902155L (sv) Serum antibodies
WO2000004391A3 (en) Prostate cancer assays and related methods
JPS583671B2 (ja) アポグルコ−スオキシダ−ゼの、フラビンアデニンジヌクレオチド及びその誘導体と結合する能力を増大する方法、複合体並びに液体媒体中のリガンドを測定するための均一系特異的結合分析法、均一系免疫分析法、試薬及